[144] Amneal Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Amneal Pharmaceuticals, Inc. (AMRX) reports a proposed sale of 104,244 common shares with an aggregate market value of $969,469, to be effected approximately on 08/20/2025 on NASDAQ through Charles Schwab.

The filing shows those 104,244 shares were acquired as restricted stock awards on multiple dates between 02/27/2022 and 03/03/2024 and paid as equity compensation. The issuer's total outstanding shares are reported as 314,079,309. The filing also discloses a prior sale by an identified seller, Andrew Boyer, of 33,436 shares on 08/12/2025 for $302,694. The signer certifies no undisclosed material adverse information and includes the standard Rule 144 representations.

Positive

• Discloses proposed sale of 104,244 shares valued at $969,469
• Broker and exchange identified: Charles Schwab and NASDAQ
• Complete acquisition history provided showing the shares derive from restricted stock awards
• Includes recent prior sale of 33,436 shares with gross proceeds reported

Negative

• Insider/beneficial owner reported a recent sale of 33,436 shares on 08/12/2025

Insights

Securities Analyst

TL;DR: Routine Rule 144 filing disclosing planned sale of restricted stock awards totaling 104,244 shares; prior sale of 33,436 shares noted.

The filing is a standard disclosure under Rule 144 showing an insider or beneficial owner intends to sell 104,244 shares valued at $969,469, with the transactions to be executed through Charles Schwab on NASDAQ around 08/20/2025. Acquisition records tie the shares to restricted stock awards granted between 2022 and 2024 and paid as equity compensation, indicating these are unlocked company awards rather than open-market purchases. The prior reported sale of 33,436 shares for $302,694 on 08/12/2025 is included as required.

Compliance Officer

TL;DR: Filing appears procedurally complete for Rule 144 disclosure; includes acquisition history and broker details.

The form contains the essential elements required for Rule 144 notices: class of security, broker name and address, number of shares, aggregate market value, outstanding shares, approximate sale date, exchange, acquisition dates and nature, and recent sales within three months. The signer declares no material nonpublic information, aligning with the attestation typically required to support Rule 144 sales. The document does not include additional context such as the seller's relationship to the issuer beyond what is listed.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab Corporation 3000 Schwab Way Westlake TX 76262	104244	969469.00	314079309	08/20/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/27/2022	Restricted Stock Award	Issuer			7811	02/27/2022	Equity Compensation
Common	03/01/2022	Restricted Stock Award	Issuer			21791	03/01/2022	Equity Compensation
Common	02/27/2024	Restricted Stock Award	Issuer			15107	02/27/2024	Equity Compensation
Common	03/01/2024	Restricted Stock Award	Issuer			15152	03/01/2024	Equity Compensation
Common	03/03/2024	Restricted Stock Award	Issuer			44383	03/03/2024	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Andrew Boyer 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807	Common	08/12/2025	33436	302694.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for AMRX disclose?

The filing discloses a proposed sale of 104,244 common shares valued at $969,469, with an approximate sale date of 08/20/2025 on NASDAQ through Charles Schwab.

Where did the 104,244 shares covered by the Form 144 come from?

Those shares were acquired as restricted stock awards between 02/27/2022 and 03/03/2024 and were paid as equity compensation.

Does the filing report any recent sales by the seller?

Yes. The filing reports a sale by Andrew Boyer of 33,436 shares on 08/12/2025 for $302,694.

What is the issuer's reported number of outstanding shares?

The filing lists 314,079,309 shares outstanding.

Which broker will handle the proposed transaction?

The broker listed is Charles Schwab Corporation, 3000 Schwab Way, Westlake TX 76262.

Does the filer make any attestation in the Form 144?

Yes. The signer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.